Hina Dave, MD
Clinical Neurophysiology · Houston, TXNPI 1750543328
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. UCB, Inc. accounts for 75.4% of it on its own, with 13 other manufacturers making up the rest.
Across 136 payments — averaging $354.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$36K
- Neurelis, Inc.$6K
- Medtronic$3K
- Neuropace, Inc.$2K
- SK Life Science, Inc.$355
- Jazz Pharmaceuticals Inc.$260
- plus $709 from 8 others
Across 14 payments — averaging $14,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$164K
- UCB, Inc.$32K
What the payments were for
- Consulting fees$22,93448%
- Speaking & faculty fees$15,08031%
- Travel & lodging$5,60912%
- Food & beverage$4,5229%
- Education$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 73 | $36,282 |
| Neurelis, Inc. | 11 | $5,708 |
| Medtronic | 8 | $2,859 |
| Neuropace, Inc. | 11 | $1,973 |
| SK Life Science, Inc. | 12 | $355 |
| Jazz Pharmaceuticals Inc. | 9 | $260 |
| Greenwich Biosciences, Inc. | 2 | $238 |
| Sumitomo Pharma America, Inc. | 3 | $150 |
| Silk Road Medical, Inc. | 1 | $97 |
| Pulmonx Corporation | 1 | $92 |
| Catalyst Pharmaceuticals, Inc. | 2 | $49 |
| Monteris Medical Corporation | 1 | $34 |
| Johnson & Johnson | 1 | $25 |
| Livanova USA, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Briviact$25,908
- Fintepla$7,086
- VALTOCO$5,559
- PERCEPT PC BRAINSENSE$2,454
- Nayzilam$1,800
- RNS Neurostimulator Kit$1,743
- Epidiolex$339
- ACTIVA PC$231
- RNS System$129
- APTIOM$115
- XCOPRI$104
How this compares
$48,147 in reported general payments places this provider in the 85th percentile of 50 clinical neurophysiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 23 | $445,114 |
| EpidiolexCannabidiol (Cbd) | 31 | $211,042 |
| BriviactBrivaracetam | 15 | $36,331 |
| KeppraLevetiracetam | 12 | $17,075 |
| TrileptalOxcarbazepine | 12 | $11,999 |
| Levetiracetam | 65 | $3,447 |
| Carbamazepine ErCarbamazepine | 12 | $3,118 |
| Oxcarbazepine | 22 | $3,047 |
| Lamotrigine | 29 | $646 |
| Zonisamide | 14 | $592 |
| Clonazepam | 32 | $328 |
| Divalproex Sodium | 11 | $296 |
| Topiramate | 15 | $120 |
| Trazodone Hcl | 20 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact | $36,282 | $481,44538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 50 clinical neurophysiology providers in Texas.
Other clinical neurophysiology in Houston
- Thy NguyenHouston$133K
- Nora Vanegas ArroyaveHouston$82K
- Samden LhatooHouston$66K
- Omotola HopeHouston$63K
- Monika UmmatHouston$36K
- Sudha TallavajhulaHouston$14K
- Victor LevinHouston$10K
- Shaun SmartHouston$9K
- Kristin BrownHouston$5K
- Jay GavvalaHouston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.